NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes
Jonas P. Becker, Dominic Helm, Mandy Rettel, Frank Stein, Alejandro Hernandez‐Sanchez, Katharina Urban, Johannes Gebert, Matthias Kloor, Gabriele Neu‐Yilik, Magnus von Knebel Doeberitz, Matthias W. Hentze, Andreas E. Kulozik
Abstract
T cell responses in an HLA-A∗02:01 transgenic mouse model. Our data show directly that pharmacological NMD inhibition augments HLA class I-mediated presentation of immunogenic frameshift-derived InDel neoepitopes thus highlighting the clinical potential of NMD inhibition in anti-cancer immunotherapy strategies.
Topics & Concepts
Frameshift mutationINDEL MutationBiologyIndelMHC class ICancer researchCD8GeneticsImmune systemMutationGeneSingle-nucleotide polymorphismGenotypevaccines and immunoinformatics approachesImmunotherapy and Immune ResponsesPeptidase Inhibition and Analysis